Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Active not recruiting 4Unknown 3Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Urothelial Carcinoma of the Bladder 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Transurethral Resection of Bladder × Genitourinary × Clear all
NCT02710734 2026-05-22

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Fox Chase Cancer Center

Phase 2 Completed
78 enrolled
Genitourinary

Urothelial Carcinoma of the Bladder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡